



# **CMBI Credit Commentary**

## Yestar – can it avert a default?

YESTHEA 6.9 Sep'21 45/55

Despite management's expectation of a recovering operation in 2H2020 (Guidance of 2H20's double-digit revenue growth vs. -30% yoy in 1H2020), We think Yestar's distressed exchange is a highly likely scenario. This is in view of Yestar's lackluster operating cash flow generation. The company expects RMB 200m operating cash inflow in 2H2020, compared to RMB 264 million achieved in 1H2020 as per Debtwire.

As a result, Yestar's weak liquidity will remain, in our view. The company only had a cash balance of RMB 709m, as of Jun, 2020; against RMB 1,415m of USD bond maturing on 15 Sep 2021. Prior to that, Yestar also faces mounting acquisition consideration payments (RMB 236m due by 31 Mar 2021, and another RMB 236m by 31 Aug 2021).

There are several sizable payments required before its USD bond comes due on 15 Sep 2020. We hence initiate an UW, and see its FV at 39, equal to its recovery value.

Our recovery value analysis shows FV of Yestar at 39, providing a floor value to its USD bond which has subsidiaries guarantee of two offshore companies – Yestar Asia Company Ltd and Yestar International (HK) Company Ltd – that own onshore operating subsidiaries of Yestar.

According to its Offering Circular, in an event of bankruptcy, liquidation or reorganization of Yestar's Non-Guarantor Subsidiaries, the Non-Guarantor Subsidiaries will pay holders of their debt and their trade creditors before they will distribute any assets to the company.

Hence we assess onshore bank loans, trade payables and wage payables as priority liabilities.

Given Yestar is an asset-light medical consumable distributor, bulk of its asset value rests in trade receivables from hospitals and inventories. We ascribe 30% discount rate(haircut) assumptions on trade receivables and inventories, because we deem part of the revenue is derived from repair and maintenance services after IVD distribution, we thus expect some degree of haircut on these current assets when Yestar is no longer a going-concern.

Polly Ng 吴宝玲 (852) 3657 6234 pollyng@cmbi.com.hk

Wilson Lu 路伟同 (852) 3761 8918 wilsonlu@cmbi.com.hk

**CMBI Fixed Income** fis@cmbi.com.hk



Recovery Value on Senior Unsecured Debt (RMB'million)				
('1H2020 financial statement)		<u> Haircut</u>		
<u>Assets</u>	<b>Book Value</b>	<u>Assumption</u>	Realized Value	
Cash (including Restricted Cash)	780	0%	780	
Trade Receivables	1,292	30%	905	
Inventories	807	30%	565	
Property, plant and equipment	143	40%	86	
Right-of-use assets	244	40%	146	
Goodwill	420	100%	-	
Other Intangible assets	1,075	100%	-	
Others	239	100%	-	
Total Assets	4,999		2,481	- (A)
Priority Liabilities				
Trade and bills payables	607	0%	607	
Tax and wage payables	454	0%	454	
Secured debt/Bank loans at operating subsidiaries	293	0%	293	
Total Priority Liabilities	1,354		1,354	- (B)
Residual Realized Value			1,127	- (C=A-B)
Other payables to non-controlling interests (acquisition related)*	1,158	0%	1,158	
Interest payable	25	0%	25	
Lease Liabilities and Contract Liabilities	217	0%	217	
Other payables	118	50%	59	
Other Non-Debt Liabilities	1,518		1,459	- (D)
Senior Unsecured Debt	1,414		1,414	- (E )
Recovery Value on Senior Unsecured Debt & Non-Debt Liabilities				
(= C/ E+D)			39%	

Note\* In Liquidation Scenario, we assume other acquisition related payables to minority shareholders will rank pari passu with existing USD bond due to the latest ruling of Shanghai Arbitrary Court that honor the contractual obligations of the earn-outs to minority shareholders.

### **Recent development:**

- Yestar issued a clarification citing connected person Samadikun Hartono, father of the 3 shareholders of Yestar, does not hold any interest in the company.
  - On 25 Dec 2020, Chinese media reported Samadikun Hartono, convicted for embezzlement of Indonesian government bail-out fund in 2003 and fled to China, was a key person in building business relationship for Yestar in China.
- COO resignation on 2 Nov 2020

CMB International Securities Limited

Fixed Income Department
Tel: 852 3761 8867/ 852 3657 6291
fis @cmbi.com.hk



#### **Disclosures & Disclaimers**

### **Author Certification**

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

### **Important Disclosures**

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIS does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIS recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIS, solely for the purpose of supplying information to the clients of CMBIS and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIS nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIS has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIS provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIS may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIS may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIS may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIS may have a conflict of interest that could affect the objectivity of this report and CMBIS will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIS.

Additional information on recommended securities is available upon request.

Disclosure:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc..,) of the Order, and may not be provided to any other person without the prior written consent of CMBIS.

For recipients of this document in the United States

CMBIS is not a registered broker-dealer in the United States. As a result, CMBIS is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.